APA
Qin S., Chan S. L., Sukeepaisarnjaroen W., Han G., Choo S. P., Sriuranpong V., Pan H., Yau T., Guo Y., Chen M., Ren Z., Xu J., Yen C., Lin Z., Manenti L., Gu Y., Sun Y., Tiedt R., Hao L., Song W. & Tanwandee T. (2019). A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. : Therapeutic advances in medical oncology.
Chicago
Qin Shukui, Chan Stephen Lam, Sukeepaisarnjaroen Wattana, Han Guohong, Choo Su Pin, Sriuranpong Virote, Pan Hongming, Yau Thomas, Guo Yabing, Chen Minshan, Ren Zhenggang, Xu Jianming, Yen Chia-Jui, Lin Zhong-Zhe, Manenti Luigi, Gu Yi, Sun Yongjian, Tiedt Ralph, Hao Lu, Song Wenjie and Tanwandee Tawesak. 2019. A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. : Therapeutic advances in medical oncology.
Harvard
Qin S., Chan S. L., Sukeepaisarnjaroen W., Han G., Choo S. P., Sriuranpong V., Pan H., Yau T., Guo Y., Chen M., Ren Z., Xu J., Yen C., Lin Z., Manenti L., Gu Y., Sun Y., Tiedt R., Hao L., Song W. and Tanwandee T. (2019). A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. : Therapeutic advances in medical oncology.
MLA
Qin Shukui, Chan Stephen Lam, Sukeepaisarnjaroen Wattana, Han Guohong, Choo Su Pin, Sriuranpong Virote, Pan Hongming, Yau Thomas, Guo Yabing, Chen Minshan, Ren Zhenggang, Xu Jianming, Yen Chia-Jui, Lin Zhong-Zhe, Manenti Luigi, Gu Yi, Sun Yongjian, Tiedt Ralph, Hao Lu, Song Wenjie and Tanwandee Tawesak. A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. : Therapeutic advances in medical oncology. 2019.